Implications Of Targeting Cell States
Targeting cell states (i.e., distinct subpopulations within the same tumor) has several major implications: It addresses intrinsic tumor heterogeneity and plasticity as a cause of resistance. The authors describe that...
Targeting cell states (i.e., distinct subpopulations within the same tumor) has several major implications: It addresses intrinsic tumor heterogeneity and plasticity as a cause of resistance. The authors describe that malignancies face barriers to durable response due to heterogeneity/plasticity, and note that coexisting molecularly distinct cell states with non overlapping drug sensitivities can drive therapeutic resistance.[:cite[1]{ln=1}] They also point out that cancer cells can transdifferentiate, enabling initially sensitive states to acquire resistance through genetic/epigenetic changes.[:cite[1]{ln=3}] It enables combination strategies that are not dependent on “cell autonomous synergy,” but on covering complementary state specific vulnerabilities. The paper proposes that an effective approach may be combinations that target orthogonal dependencies of coexisting states rather than relying on cell autonomous synergy.[:cite[1]{ln=4}] It supports mechanism based selection of drugs that are state specific (and therefore more rational than one size fits all therapy). The study uses inferred master regulator (MR) proteins as “mechanistic determinants” of transcriptional cell states and presents a strategy to pharmacologically target cell state specific MR proteins.[:cite[2]{ln=1}] Because MR activity is inferred from differential expression of transcriptional targets, they claim this produces a mechanism based framework to prioritize cell state specific drug combinations from single cell profiles.[:cite[2]{ln=4}] It improves the odds of finding drugs that work against multiple coexisting states simultaneously. Using MR directed predictions, the study validates state selective drug sensitivity for 8 out of 9 (89%) drugs in vivo.[:cite[3]{ln=5}] They report that, compared with monotherapy, co administering drugs targeting complementary states significantly prolonged survival across virtually all combinations , including avapritinib + ruxolitinib extending median survival nearly threefold vs vehicle and 1.5 fold vs avapritinib alone.[:cite[3]{ln=6}] It can reveal both shared and state /sample specific dependencies. While many essential MRs are conserved, VIPER analysis also captures a “small repertoire” of sample /mutation specific dependencies, highlighting idiosyncratic dependencies beyond the core shared program.[:cite[4]{ln=1}] This implies that state targeting may need some contextual adaptation while still leveraging recurrent state programs. It can yield clinically translatable combination regimens. The authors state that their approach culminated in “clinically actionable combinations” poised for rapid clinical translation, giving examples such as avapritinib/ruxolitinib and avapritinib/larotrectinib.[:cite[5]{ln=3}] If you want, I can also extract the specific mechanistic rationale the paper uses (MR activity inversion) and connect it directly to why complementary state combinations improve survival, using only the text from the study.